Dr. Stuart Titus to be one of 65 cannabis experts to speak on cannabis and CBD at special public hearing to determine how to regulate products containing cannabis and its derivatives.
The U.S. Food & Drug Administration will be holding a public hearing to gather opinions on legalizing CBD from cannabis experts and advocates later this month. The FDA will consider these opinions as the agency creates its framework to regulate the marketing of cannabis and cannabis-derived products, including the use of CBD in dietary supplements and foods.
Medical Marijuana, Inc. CEO Dr. Stuart Titus has been invited to speak during this public hearing to share his extensive expertise he has gathered from his years in the medical cannabis and CBD spaces.
Under Dr. Titus’s tenure as CEO and president of Medical Marijuana, Inc., our portfolio of companies have created dozens of new consumer CBD products aimed at general wellness, expanded access to CBD to patients and consumers in over 40 countries, with a focus on North America, Latin America and Europe. We have also pursued new drug status for products aimed at opioid addiction, the nausea and vomiting linked to chemotherapy and AIDS, and drug-induced psychosis.
Dr. Titus earned his PhD from Open International University, an educational organization affiliated with the World Health Organization, and practiced as a physiologist for over fifteen years. He holds a Fellowship with the American Academy of Pain Management and clinical association with the American Association of Integrative Medicine.
Dr. Titus will be one of 65 speakers chosen from a pool of nearly 400 candidates. In his role with our company, Dr. Titus speaks at dozens of events every year around the world, discussing the history, physical effects, potential pharmacology, research, and case studies linked to cannabis and hemp-derived CBD in particular.
“I’m honored to be given this opportunity to speak on a national stage about why cannabidiol ( CBD) is near to my heart and why everyone in the United States should have access to it,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “We look forward to the FDA creating clear guidelines for the sale and production of CBD as we hope many of our competitors and business partners will be held to the highest-standards of quality and consistency like those that we ensure our customers with every product that we sell.”
Medical Marijuana, Inc. became the first company to create and distribute CBD hemp oil products in 2012 when we launched the first of our CBD consumer products. Since then, we have become consumers’ first choice in CBD products for their entire family, including their pets. This is largely due to our dedication to producing only the highest quality products, which has led us to create the strictest safety and quality standards in the CBD industry.
According to its website, the FDA Public Hearing on Scientific Data and Information about Products Containing Cannabis or Cannabis-Derived Compounds “will help them obtain scientific data and information about the safety, manufacturing, product quality, marketing, labeling, and sale of products containing cannabis or cannabis-derived compounds”.
The FDA is holding this public hearing as a response to the growing popularity of cannabis products, including those containing cannabidiol ( CBD). The agency acknowledges interest in cannabis products from both consumers and manufacturers, creating a need for a clear regulatory framework. These include products marketed as human drugs, dietary supplements, conventional foods, animal foods and drugs, cosmetics, bath and beauty products, and much more.
The FDA hearing will also seek to add clarity to the agency’s position on hemp-derived CBD following the legalization of the domestic hemp industry following the 2018 Farm Bill. The omnibus law fully legalized the hemp industry in the U.S. by removing hemp completely from the Controlled Substances Act (CSA) and giving states the power to regulate domestic hemp cultivation.
With hemp-derived CBD removed from the CSA, the task of regulating products made with CBD falls on the FDA, who up until this point have only sporadically mailed warning letters to CBD companies who explicitly made medical claims about the effects of CBD in their marketing.
The public hearing will be held on May 31, 2019, from 8 am to 6 pm. Dr. Titus will give his oral comments between 8:00 am and 10:30 am. The FDA will webcast this public hearing. Click here to view the hearing via webcast.
Want your voice to be heard? You can send your comments on CBD and how it should be regulated to the FDA until July 2, 2019. Get started here.